Skip to content

Effect of Aragvadhadi Taila and gel in Shvitra

Pharmaceutical standardization of two different dosages forms of Aragvadhadi Taila and their comparative efficacy in the management of Shvitra (Vitiligo)

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/01/011120
Enrollment
60
Registered
2018-01-03
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- patients having signs and symptoms of Shvitra (Vitiligo) Health Condition 2: L80- Vitiligo

Interventions

Intervention1: Aragvadhadi Taila: Aragvadhadi Taila QS for external application and Rasayana churna 3 gm two times/day after meal with honey, internally, for duration of 8 weeks and follow up of 4 we

Sponsors

Institute for Post Graduate Teaching and Research in Ayurveda
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients having signs and symptoms of Shvitra (vitiligo). 2. Patient between the age-18 to 60 years. 3. Patients with chronicity of less than 10 years

Exclusion criteria

Exclusion criteria: 1. Patients with Chronicity more than 10 years. 2. Patients having serious cardiac, renal, hepatic diseases, major illness like IDDM, NIDDM, patches due to burning, chemical explosion, any other serious systemic illness. 3. Gravid and lactating women. • Women in fertile age planning for conception within next 3 months. • Cases with Asadhya Lakshana of Shvitra

Design outcomes

Primary

MeasureTime frame
1 Marked improvement in Vitiligo patches and other clinical features 2 complete remission of Vitiligo lesions 3 Non recurrence after the follow up periodTimepoint: 56 days

Secondary

MeasureTime frame
1 Improvement in skin texture 2 Improvement in Dermatological QOLTimepoint: 28 days

Countries

India

Contacts

Public ContactProf BJ Patgiri

IPGT and RA

patgiri124@gmail.com9426947438

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026